209256-40-6

Basic information

• Product Name: 2,3-dihydrobenzofuran-4-carboxylic acid
• Synonyms: 2,3-dihydrobenzofuran-4-carboxylic acid;2,3-Dihydrobenzo[b]furan-4-carboxylic acid;2,3-dihydro-1-benzofuran-4-carboxylic acid;2,3-Dihydro-4-benzofurancarboxylic Acid;2,3 dihdyrobenzofuran 4 carboxylic acid
• CAS NO: 209256-40-6
• Molecular Formula: C9H8O3
• Molecular Weight: 164.15802
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 209256-40-6.mol

Chemical Properties

• Boiling Point: 328℃
• Flash Point: 139℃
• Appearance: /
• Density: 1.344
• Vapor Pressure: 7.88E-05mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: 2-8°C
• PKA: 3.67±0.20(Predicted)
• CAS DataBase Reference: 2,3-dihydrobenzofuran-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydrobenzofuran-4-carboxylic acid(209256-40-6)
• EPA Substance Registry System: 2,3-dihydrobenzofuran-4-carboxylic acid(209256-40-6)

Safety Data

• Hazardous Substances Data: 209256-40-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydrobenzofuran-4-carboxylic acid is used as a key intermediate for the synthesis of oxazolidine compounds, which are known as orexin receptor antagonists. These antagonists have potential applications in the treatment of various central nervous system disorders, such as insomnia, depression, and addiction, by targeting the orexin system in the brain.
Used in Chemical Synthesis:
2,3-dihydrobenzofuran-4-carboxylic acid can also be utilized as a starting material for the preparation of various other organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its unique structure and functional groups make it a valuable building block for the development of novel molecules with diverse applications.

InChI:InChI=1/C9H8O3/c10-9(11)7-2-1-3-8-6(7)4-5-12-8/h1-3H,4-5H2,(H,10,11)

Upstream product

• 166599-84-4 benzofuran-4-carboxylic acid 

Downstream Products

• 209256-41-7 (2,3-dihydro-benzofuran-4-yl)-methanol 
• 1220346-76-8 2,3-dihydro-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-oxazolidin-2-ylmethyl]-amide 
• 1137129-70-4 (S)-2,3-dihydro-benzofuran-4-carboxylic acid {1-[5-(3-chloro-phenyl)-2-pyridin-4-yl-thiazole-4-carbonyl]-pyrrolidin-2-ylmethyl}-amide 
• 209257-15-8 trans-[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methanamine 
• 209256-42-8 2,3-dihydro-1-benzofuran-4-carbaldehyde 

Relevant articles and documents

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES

The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.

TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES

The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.